via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:KALY) (“KALY”) and Puration, Inc, (USOTC:PURA) (“PURA”) today announced a new 25 mg CBD Extract formulation for beverage infusion. KALY owns and manages a patented cannabis extraction process. PURA has licensed the KALY patent for beverage infusion. PURA currently produces EVERx CBD Sports Water infused with 10 mg of CBD. Together KALY and PURA are designing a new private labeled CBD infused beverage for Generex Biotechnology, Inc. (OTCBB:GNBT). In response to feedback from PURA’s EVERx distributors, KALY and PURA are now working together to refine a new 25 mg CBD extract formulation.
“Through the retail outlets our distributors serve, we are getting feedback that there is an unserved demand for CBD infused beverages with 25 mg of CBD,” said Brian Shible, CEO of PURA. “Not many beverages even have the 10 mg concentration we currently deliver. Next to no beverage comes with 25 mg. We believe we can deliver 25 mg and still maintain our clean refreshing taste. We are considering introducing this first 25 mg beverage exclusively under the Generex label.”
Puration launched the EVERx CBD Sports Waters in the spring of 2017. The company’s sales grew 600% in the first year after the launch of EVERx. Kiwi Strawberry and Lemon Lime flavors are now available in addition to the Original EVERx CBD Infused Sports Water. EVERx has more than twice the CBD of most CBD infused waters on the market. A proprietary technology enables EVERx to suspend more CBD than its competitors and still have a crystal-clear appearance and a refreshing taste.
KALY recently acquired a biotech company with a patented cannabis extraction process. Accordingly, KALY updated its overall business plan (a presentation on the company’s updated business plan is available on KALY’s website). Hemp4mula is part of the updated business plan which management is rapidly executing. The company recently announced a $300,000 hemp-derived CBD extraction contract with Puration, Inc. (USOTC:PURA). The CBD Kali-extracts will produce is to support PURA’s contract to produce a private labeled CBD infused Water for Generex.
Goldman Small Cap Research Report published an analyst research report on KALY this past Tuesday, January 8, 2019 that highlights KALY’s cannabis pharmaceutical value. The report is available under “research” on the OTCMarkets website. The research report is the first report from Goldman Small Cap Research as part of an ongoing research engagement. The report outlines the company’s current positioning and potential, upcoming milestones. The report is intended to augment the current information available on the OTCMarkets website. The report is also available to read or download, along with associated disclosures and disclaimers, at www.GoldmanResearch.com.
To learn more about the company visit https://www.kali-extracts.com/
For more information on Puration, visit http://www.purationinc.com
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.